Levobunolol (hydrochloride)

• UNSPSC Description:

  Levobunolol (l-Bunolol) hydrochloride is a potent and nonselective β-adrenergic receptor antagonist. Levobunolol hydrochloride is an ocular hypotensive agent and lowers mean intraocular pressure (IOP). Levobunolol hydrochloride can be used for glaucoma and superior oblique myokymia (SOM) research[1][2][3].

• Target Antigen:

  Adrenergic Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;Neuronal Signaling

• Field of Research:

  Others; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/Levobunolol-hydrochloride.html

• Purity:

  99.89

• Solubility:

  DMSO : ≥ 62.5 mg/mL|H2O : 50 mg/mL (ultrasonic)

• Smiles:

  O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C.[H]Cl

• Molecular Weight:

  327.85

• References & Citations:

  [1]Mohammadi M, et al. Injectable drug depot engineered to release multiple ophthalmic therapeutic agents with precise time profiles for postoperative treatment following ocular surgery. Acta Biomater. 2018 Jun;73:90-102.|[2]Kumar, N, et al. Extended levobunolol release from Eudragit nanoparticle-laden contact lenses for glaucoma therapy. Futur J Pharm Sci 6, 109 (2020).|[3]Zhang M, et al. Superior oblique myokymia treated with levobunolol. J AAPOS. 2018 Feb;22(1):67-69.e2.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, sealed storage, away from moisture)

• Clinical Information:

  Launched

• CAS Number:

  27912-14-7